Grant: Collaborative Research and Development Grants
University of Alberta
$67,700.00
X-ray crystal structure analysis of phosphoglycerate kinase from gram-negative pathogens: validation of an anti-microbial drug target
FY 2012-13
Summary
Indel Therapeutics Inc. of Vancouver, British Columbia has established an industrial/academic collaboration with the laboratory of Dr. Michael James at the University of Alberta. This collaboration will investigate a potential target identified by Indel's drug target identification platform for the development of new antimicrobials to fight drug resistance and hospital acquired infections. The James laboratory is a world leader in the field of structural biology using X-ray crystallographic techniques. It will produce highly purified target enzymes from several important oportunistic pathogens in order to determine the high resolution three dimensional structures of the target enzymes. Structure determination allows screening of compound libraries to identify potential inhibitors. Elucidation of enzyme target-inhibitor complex structures can validate Indel's predictions and allow structure-guided improvements to the lead inhibitor molecules. Increased potency and specificity will be monitored by measuring inhibition using in vitro enzyme activity assays. The societal benefit of this collaboration is that the work directly addresses the dire problem of antibiotic-resistant hospital acquired bacterial infections and the resulting economic impact to the Canadian health care system.
Program
Collaborative Research and Development Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
421876-2011
Name nom
James, Michael
Department département
Biochemistry
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
67700
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5400
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Biochemistry
Research subject fr
Biochimie
Partie
1
Nb partie
1
Application title
X-ray crystal structure analysis of phosphoglycerate kinase from gram-negative pathogens: validation of an anti-microbial drug target
Keyword
NSERC
Application summary
Indel Therapeutics Inc. of Vancouver, British Columbia has established an industrial/academic collaboration with the laboratory of Dr. Michael James at the University of Alberta. This collaboration will investigate a potential target identified by Indel's drug target identification platform for the development of new antimicrobials to fight drug resistance and hospital acquired infections. The James laboratory is a world leader in the field of structural biology using X-ray crystallographic techniques. It will produce highly purified target enzymes from several important oportunistic pathogens in order to determine the high resolution three dimensional structures of the target enzymes. Structure determination allows screening of compound libraries to identify potential inhibitors. Elucidation of enzyme target-inhibitor complex structures can validate Indel's predictions and allow structure-guided improvements to the lead inhibitor molecules. Increased potency and specificity will be monitored by measuring inhibition using in vitro enzyme activity assays. The societal benefit of this collaboration is that the work directly addresses the dire problem of antibiotic-resistant hospital acquired bacterial infections and the resulting economic impact to the Canadian health care system.